|
related topics |
{operation, international, foreign} |
{regulation, change, law} |
{control, financial, internal} |
{stock, price, operating} |
{product, market, service} |
{stock, price, share} |
{acquisition, growth, future} |
{cost, regulation, environmental} |
{customer, product, revenue} |
{operation, natural, condition} |
{debt, indebtedness, cash} |
{provision, law, control} |
{investment, property, distribution} |
{regulation, government, change} |
{personnel, key, retain} |
{product, candidate, development} |
{product, liability, claim} |
|
Risks Relating to Our Business
We have a history of operating losses and anticipate that we will continue to
incur losses for the foreseeable future.
We may be unable to acquire, or may be delayed in acquiring, Rongheng.
We may be unsuccessful in our strategy of expanding our product portfolio,
acquiring complementary businesses or integrating acquired businesses.
We may continue to experience delays in product introduction and marketing or
We may be unable to compete successfully against new and existing competitors.
If we fail to increase our brand recognition, we may face difficulty in
obtaining new customers and business partners.
Our operating results may fluctuate as a result of factors beyond our control.
We may be unable to obtain additional capital when necessary and on terms that
We may be unsuccessful in attracting or retaining key sales, marketing and other personnel.
We may be unable to manage our growth effectively.
We only offer products and services related to pharmaceuticals and, if demand
for these products and services decreases, or if competition increases, we will have no other ways to
Our business strategy to use our marketing arm to create demand for products
that we will offer exclusively through a distribution arm may fail.
Because we only recently became subject to the reporting requirements of the
Exchange Act, we have no
experience attempting to comply with public company obligations. Attempting to
comply with these requirements will increase our costs and require additional
management resources and we still may fail to comply.
If we are unable to satisfy the regulatory requirements relating to internal controls, or if our internal controls over financial reporting are not effective, our stock price could decline.
We are a holding company with no operations of our own and depend on our
Risks Relating to Doing Business in China
We face increased risks of doing business due to the extent of our operations
Fluctuations in the Chinese Renminbi could adversely affect our results of
Government control of currency conversion could adversely affect our operations
The ability of our Chinese operating subsidiaries to pay dividends may be
restricted due to our corporate structure.
We may be restricted in our ability to transfer funds to our Chinese operating
subsidiaries, which may restrict our ability to act in response to changing
China s economic, political and social conditions, and its government
policies, could adversely affect our business.
A slow-down of the Chinese economy could adversely affect our growth and
The legal system in China has inherent uncertainties that could limit the legal
We have limited business insurance coverage in China.
Any future outbreak of health epidemics, such as Severe Acute Respiratory Syndrome, or SARS, Asian Influenza, or Asian Bird Flu, or any other
epidemic in China could have a material adverse effect on our business
operations, financial condition and results of operations.
Risks Relating to Pharmaceutical Distribution in China and Wanwei
The absence of express laws and regulations in China regarding foreign
investment in China s pharmaceutical distribution sector may cause uncertainty.
Wanwei may be unable to obtain renewals of necessary pharmaceutical distribution permits.
Price control regulations may decrease our profitability.
The bidding process with respect to the purchase of pharmaceutical products may lead to reduced revenue.
If the medicines Wanwei distributes are replaced by other medicines or are removed
from China s Insurance Catalogue in the future, Wanwei s revenue may
Risks Relating to Our Common Stock
Sales of substantial amounts of our common stock in the public market could
depress the market price of our common stock.
If the ownership of our common stock continues to be highly concentrated, it
may prevent you and other stockholders from influencing corporate decisions, such as significant corporate transactions and the election and replacement or removal of directors and management, and
may also result in conflicts of interest that could cause our stock price to
Our common stock may experience extreme price and volume fluctuations, which
could lead to costly litigation for us and make an investment in us less
As a stock quoted on the OTCBB, our common
stock, which is deemed to be penny stock, currently has limited liquidity.
Full 10-K form ▸
|
|
related documents |
1030471--3/2/2009--UTSTARCOM_INC |
1331444--3/27/2009--CHINA_CLEAN_ENERGY_INC |
1030471--6/1/2006--UTSTARCOM_INC |
1030471--3/3/2008--UTSTARCOM_INC |
1239188--3/31/2008--GENERAL_STEEL_HOLDINGS_INC |
1117057--4/13/2009--American_Lorain_CORP |
1168556--3/31/2008--TIENS_BIOTECH_GROUP_USA_INC |
1368745--3/31/2008--Victory_Divide_Mining_CO |
1117057--4/15/2008--American_Lorain_CORP |
1281696--3/26/2007--BEIJING_MED_PHARM_CORP |
1123493--4/15/2008--China_Logistics_Group_Inc |
1107564--5/3/2007--NEW_FIBER_CLOTH_TECHNOLOGY_INC |
1076939--4/2/2008--SKYSTAR_BIO-PHARMACEUTICAL_CO |
1281696--3/17/2008--BMP_Sunstone_CORP |
885551--6/29/2006--VALENCE_TECHNOLOGY_INC |
1127439--12/14/2006--INTAC_INTERNATIONAL_INC |
1403853--3/11/2010--Heckmann_CORP |
1402159--3/31/2009--CHINA_PROSPEROUS_CLEAN_ENERGY_Corp |
1165780--3/30/2006--COUGAR_HOLDINGS_INC |
885551--6/5/2009--VALENCE_TECHNOLOGY_INC |
808011--12/11/2007--WINNER_MEDICAL_GROUP_INC |
922717--6/14/2010--CHINDEX_INTERNATIONAL_INC |
1394220--4/1/2008--Jade_Mountain_CORP |
1368275--10/4/2010--News_of_China_Inc |
812701--3/30/2006--CALGON_CARBON_CORPORATION |
787251--3/31/2008--CHINA_NORTH_EAST_PETROLEUM_HOLDINGS_LTD |
1030471--10/10/2007--UTSTARCOM_INC |
808011--12/19/2006--WINNER_MEDICAL_GROUP_INC |
6383--4/27/2006--MOSCOW_CABLECOM_CORP |
922717--6/14/2007--CHINDEX_INTERNATIONAL_INC |
|